ZNF217 and ovarian carcinoma: The same study also confirmed downregulation of PRSS8 after silencing ZNF217 expression indicating the significance of ZNF217 as a key regulator [93] and suggesting PRSS8 as a potential biomarker in ovarian carcinomas.